Superluminal Medicines Revenue and Competitors
Estimated Revenue & Valuation
- Superluminal Medicines's estimated annual revenue is currently $6.7M per year.
- Superluminal Medicines's estimated revenue per employee is $190,429
- Superluminal Medicines's total funding is $153M.
Employee Data
- Superluminal Medicines has 35 Employees.
- Superluminal Medicines grew their employee count by 94% last year.
Superluminal Medicines's People
| Name | Title | Email/Phone |
|---|
Superluminal Medicines Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $12.7M | 82 | -45% | $107.3M | N/A |
#2 | $0.2M | 1 | -50% | N/A | N/A |
#3 | $6.2M | 40 | 21% | N/A | N/A |
#4 | $42.2M | 218 | 4% | $165M | N/A |
#5 | $14.6M | 94 | -37% | $312.8M | N/A |
#6 | $0.3M | 2 | -67% | N/A | N/A |
#7 | $235M | 366 | -5% | $340.9M | N/A |
#8 | $56M | 289 | -7% | $7.6M | N/A |
#9 | $4.7M | 61 | 36% | N/A | N/A |
#10 | $2M | 13 | 8% | N/A | N/A |
What Is Superluminal Medicines?
Superluminal Medicines is a Boston-based generative biology and chemistry company developing a differentiated pipeline and revolutionizing the speed and accuracy of how medicine is created.\n\nOur platform creates candidate-ready compounds with unprecedented speed using a comprehensive combination of deep biology and chemistry expertise, machine learning, and proprietary big data infrastructure. \n\nThe predict-design-test architecture accurately models protein shapes and designs highly selective compounds to target the precise structural change for therapeutic effect. Our discovery engine is powered by an industry-leading, pharmacokinetic and toxicology in silico prediction capability. \n\nWith a lead program candidate expected in the near term, our proprietary pipeline validates our platform with initial programs focused on high-value GPCR targets. We’re pleased to be backed by a strong network of investors including RA Capital Management, Insight Partners, NVentures, Catalio Capital Management, Eli Lilly and Company, Gaingels, and Cooley LLP.
keywords:N/A
$153M
Total Funding
35
Number of Employees
$6.7M
Revenue (est)
94%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in Boston
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $4.1M | 35 | 13% | N/A |
#2 | $8.6M | 35 | N/A | N/A |
#3 | $7M | 35 | N/A | N/A |
#4 | $3.9M | 35 | -36% | $50M |
#5 | $6M | 35 | 0% | N/A |